Cowen analyst Ryan Blicker said he sees minimal Q4 risk versus expectations for the diabetes device stocks. He believes the long-term outlook is compelling with multiple key catalysts in 2020. The analyst said he sees the greatest potential for upward estimate revisions for Dexcom (DXCM) and it remains his top pick in the group. Blicker reiterated his Outperform rating and raised his price target to $250 from $240 on Dexcom shares, and also raised his target on Insulet (PODD) to $185 from $170, and lowered his price target on Tandem Diabetes (TNDM) to $70 from $75.